What are ADC's

Our services

ADC Review
is made possible by:

NCT01816035 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery (NCT01816035)

Trial Description
This phase I trial studies the side effects and best way of giving ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread to other parts of the body or nearby tissue and cannot be removed by surgery. Biological therapies, such as ado-trastuzumab emtansine, may stimulate the immune system in different ways and stop cancer cells from growing.

This trial is sponsored by University of WashingtonNational Cancer Institute (NCI). [1]

Study Data

  • Condition:
    • HER2/Neu Positive Breast Cancer
    • Recurrent Breast Carcinoma
    • Stage IIIB Breast Cancer
    • Stage IIIC Breast Cancer
    • Stage IV Breast Cancer
  • Interventions:
    • Drugs used in this trial
    • Other: Laboratory Biomarker Analysis
    • Other: Pharmacological Study
  • Phase: I
  • Estimated Enrollment: 20
  • Start: June 2014
  • Estimated Primary Completion: February 2016
  • Last verified: June 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 28, 2015

Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar